Ocular TherapeutixTM announces FDA acceptance of NDA resubmission for DEXTENZA®
Ocular Therapeutix™ announced it has received acknowledgement from the FDA that the NDA for DEXTENZA® has been received. DEXTENZA (dexamethasone insert) 0.4mg is Ocular Therapeutix’s lead product candidate for treatment of ocular pain following ophthalmic surgery. July 19, 2018